dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Alsina Maqueda, Maria |
dc.contributor.author | Diez Garcia, Marc |
dc.contributor.author | Tabernero Caturla, Josep |
dc.date.accessioned | 2022-08-11T11:56:02Z |
dc.date.available | 2022-08-11T11:56:02Z |
dc.date.issued | 2022-03-10 |
dc.identifier.citation | Alsina M, Tabernero J, Diez M. Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond. Cancers. 2022 Mar 10;14(6):1408. |
dc.identifier.issn | 2072-6694 |
dc.identifier.uri | https://hdl.handle.net/11351/7992 |
dc.description | Gastric cancer; Molecular approach; Third line of treatment |
dc.description.abstract | Gastric and gastro-oesophageal junction cancer (GC) represent a global healthcare problem being the fifth most common tumour type and the fourth cause of cancer mortality. Extremely poor median survival of approximately 10 months is normally reported within advanced GC patients, mainly secondary to two factors, i.e., the fragility of these patients and the aggressiveness of this disease. In this context, the correct treatment of GC patients requires not only a multidisciplinary team with special attention to palliative and nutritional care but also a close follow-up with regular monitoring of disease symptoms and tumour evaluation. Sequential treatment lines with few toxic adverse events have emerged as the best therapeutic approach, and a third line of therapy could further improve survival and quality of life of GC patients. Chemotherapy, immunotherapy, and targeted agents -when indicated- constitute the treatment armamentarium of these patients. In this review, we discuss treatment options in the refractory setting as well as novel approaches to overcome the poor prognosis of GC. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Cancers;14(6) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Estómac - Càncer - Tractament |
dc.subject | Medicaments antineoplàstics - Efectes secundaris |
dc.subject.mesh | Stomach Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Agents |
dc.subject.mesh | /adverse effects |
dc.title | Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/cancers14061408 |
dc.subject.decs | neoplasias gástricas |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | antineoplásicos |
dc.subject.decs | /efectos adversos |
dc.relation.publishversion | https://doi.org/10.3390/cancers14061408 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Alsina M] Gastrointestinal & Endocrine Tumours Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Medical Oncology Department, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain. [Tabernero J, Diez M] Gastrointestinal & Endocrine Tumours Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain |
dc.identifier.pmid | 35326560 |
dc.identifier.wos | 000775920300001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |